Navigation Links
Foundation Venture Capital Group commits up to $500,000 in start-up advancing technology platform for tissue visualization
Date:2/23/2016

NEW BRUNSWICK, N.J., Feb. 23, 2016 /PRNewswire-USNewswire/ -- James M. Golubieski, president of Foundation Venture Capital Group, LLC, announced today that the company has made a $500,000 commitment to Visikol, Inc., a new start-up company from Rutgers University that has developed a versatile biological clearing agent called Visikol that penetrates tissue and renders it transparent without causing structural damage.

The Visikol technology has applications in the fields of toxicology, pre-clinical drug development, clinical diagnostics, basic research and plant biology as tissues can be easily visualized in 3 dimensions.

The company was founded by PhD candidate Michael Johnson, chief executive officer; Nick Crider, chief operating officer and PhD candidate Tom Villani, chief scientific officer. It has exclusively licensed the worldwide rights to the technology through an agreement with Rutgers. This patent-pending technology was invented by Mr. Villani, while he was a graduate student, along with Rutgers professors Drs. James Simon and Adolfina Koroch

The founders explained that the product is a nondestructive optical clearing agent offering a high level of transparency that greatly reduces problems with light scattering and enables high resolution images to be captured from biological tissues.

"This biological clearing agent is transformative in its ability to easily, effectively and quickly clear animal and plant tissue," said Mr. Johnson. "Because it can clear whole tissue, it allows for 3-D visualization of tissue instead of the traditional slicing based 2-D visualization approach."

With the invention of the microscope in the late 1500s, researchers have been seeking better ways to visualize the inside of biological tissue. Up until recently, this meant slicing tissue into thin slices so light could penetrate enough to illuminate the inside of the tissue.

"While many modern techniques now exist to provide 3-D visualization of tissue, we are excited about this development in the biological clearing arena because current techniques obscure important cellular and biochemical information and researchers must still resort to slicing tissue to recover data," explained George F. Heinrich, MD, vice chair and CEO of Foundation Venture Capital Group, an affiliate of New Jersey Health Foundation. "This new platform adds significant value to fields like drug development and cancer diagnostics as it allows for more accurate information to be obtained from tissue."

Biologists, biochemists and geneticists who need to visualize the anatomical location of cellular structure, proteins/enzymes, mRNA, and reporter genes within whole tissue are among those who can benefit from this innovative product, which can be used with light microscopy, fluorescence microscopy, confocal microscopy and single/multiphoton microscopy. It also has an educational component, providing a valuable addition to any biology classroom.

For more information contact Mike Wiley, vice president of Foundation Venture Capital Group at mwiley@njhf.org or (908) 731-6612.

About Foundation Venture Capital Group

Foundation Venture Capital Group, an affiliate of New Jersey Health Foundation, makes private equity investments to participate in establishing and managing biomedical start- up companies in New Jersey headed toward commercialization.  In addition to Visikol, its portfolio companies currently include:

  • Actinobac Biomed Inc., developing a therapeutic agent targeting blood cells for the treatment of hematological malignancies such as leukemia and lymphomas;
  • Affineti Biologics, Inc., advancing research in the development of therapeutic and diagnostic products based on new discoveries in oral biology and dental medicine;
  • CellXplore, Inc., engaged in the development of biomarker-based in vitro diagnostic assays for cancer;
  • Celvive, Inc., working to develop technology to treat patients with chronic spinal cord injuries with their own adult stem cells;
  • Durin Technologies, working to develop a blood test to diagnose  and assess severity of Alzheimer's, Parkinson's and other neurodegenerative diseases;
  • GeneAssess, Inc., developing the FRY gene as a predictive biomarker for breast and other cancers;
  • MentiNova, Inc., working to validate a drug that reduces the side effects of L-Dopa Induced Dyskinesia 
  • NovoPedics, Inc., developing an implantable meniscus replacement/regeneration medical device to restore mobility to patients suffering from severe meniscus knee injuries
  • Snowdon Pharmaceuticals, Inc., a drug discovery company focused on several major therapeutic areas and providing computational tools to rapidly identify high-value molecules from their library of vendor-available compounds

 


'/>"/>
SOURCE Foundation Venture Capital Group, LLC
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill
2. NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of ND0612 for Parkinsons Disease
3. Betty Ford Center, Hazelden Foundation Pursue Possible Alliance
4. W.K. Kellogg Foundation announces Mission Driven Investment in SeeChange Health
5. Alzheimers Drug Discovery Foundation Supports Madera Biosciences to Advance Small Molecule Drugs that Upregulate apoE
6. MediScripts and The Jed Foundation Team Up to Offer Physicians Additional Resources to Support Emotional Health of College-Age Students
7. BIRD - Israel - U.S. Binational Industrial R&D Foundation to Invest $11 Million in 14 new Projects
8. Belrose Pharma Acquires Enzons Advanced Drug Formulation Technology and Clinical Assets as Foundation for Driving Development of More Effective Injectable and Sustained Release Therapies
9. Ellen MacArthur Foundation presenterar Philips som global partner vid det konstituerande internationella toppmötet om cirkulär ekonomi
10. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
11. Epilepsy Foundation Launches The "Epilepsy Innovation Seal Of Excellence" Recognizing Groundbreaking Product Candidates For People With Epilepsy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/3/2020)... ... 03, 2020 , ... In Partnership with the Smiles for Everyone Foundation ... at its Burleson, TX office on February 8th. , Dental services provided include same-day ... and extractions . For more information, please visit the Monarch Dental website ...
(Date:1/3/2020)... ... 03, 2020 , ... American actor, Laurence Fishburne, is well-known for his performances ... most know him for the movies he takes part in, he is also the ... explores a vast range of topics to educate its viewers about many issues taking ...
(Date:12/31/2019)... ... December 31, 2019 , ... ... to its Scientific Advisory Board. NanoFUSE Biologics offers a biologically enhanced synthetic therapeutic, ... medical device. , President of NanoFUSE Biologics, Jake Lubinski, said, “We’re fortunate to ...
Breaking Medicine Technology:
(Date:1/10/2020)... ... 2020 , ... Sigma Theta Tau International Honor Society of Nursing (Sigma) was ... awards are regarded as one of the most important and prestigious designations of excellence ... Year competition has recognized Sigma for the last 11 consecutive years. , The following ...
(Date:1/10/2020)... , ... January 10, 2020 , ... ... has announced that it will be attending the HIMSS (Healthcare Information and Management ... , HIMSS is the can’t-miss health information and technology event of the year, ...
(Date:1/8/2020)... ... 08, 2020 , ... Mirror Mirror Beauty Boutique ... of Memorial Readers’ Choice Awards. Located adjacent to Vitenas Cosmetic Surgery, the ... Memorial reflects Mirror Mirror Beauty Boutique’s commitment to the hottest noninvasive trends that ...
(Date:1/7/2020)... ... January 07, 2020 , ... ... and services, today identified six trends that will significantly impact the point of ... “Arguably, the time shared between a provider and patient is the most important ...
(Date:1/7/2020)... Pa. (PRWEB) , ... January 07, 2020 , ... Iconic ... musical talent and being one of the most successful female artists of all time, ... started her first Las Vegas residency and shared in interviews her secrets to making ...
Breaking Medicine News(10 mins):